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Objective. Present our experience managing bladder cancer following liver and renal transplantation. Methods. Single institution
retrospective review ofpatientsdiagnosedwithbladderurothelialcarcinoma(BUC) followingsolidorgantransplantationbetween
January 1992 and December 2007. Results. Of the 2,925 renal and 2,761 liver transplant recipients reviewed, we identiﬁed eleven
patients (0.2%) following transplant diagnosed with BUC. Two patients with low grade T1 TCC were managed by TURBT. Three
patients with CIS and one patient with T1 low grade BUC were treated by TURBT and adjuvant BCG. All four are alive and free
of recurrence at a mean follow-up of 51 ± 22 months. One patient with T1 high grade BUC underwent radical cystectomy and
remains disease free with a follow-up of 98 months. Muscle invasive TCC was diagnosed in four patients at a median of 3.6 years
following transplantation. Two patients are recurrence free at 24 and 36 months following radical cystectomy. Urinary diversion
and palliative XRT were performed in one patient with un-resectable disease. Conclusions. Bladder cancer is uncommonfollowing
renal and liver transplantation, but it can be managed successfully with local and/or extirpative therapy. The use of intravesical
BCG is possible in select immunosuppressed patients.
1.Introduction
Renal and liver transplantation are the optimal treatments
for end-stage renal and liver disease [1, 2]. While the devel-
opment of bladder cancer following renal and liver trans-
plantation is quite rare [3], transplant recipients have an
increased incidence of bladder cancer [4, 5], ranging from
0.08% to 2.1% [6, 7], and frequently present with higher-
stage bladder cancer compared to the general population
[5]. Optimal management of bladder cancer among renal
and liver transplant recipients is not well deﬁned. Most
management strategies have only been brieﬂy described in
anecdotal case reports [8]a n dr e t r o s p e c t i v es e r i e s[ 7]. We
present our single institution experience managing bladder
cancer after renal and liver transplantation.
2.PatientsandMethods
Through an Institutional Review Board approved protocol,
we retrospectively reviewed our institutional transplant
database to identify patients diagnosed with bladder urothe-
lial carcinoma (BUC) following renal and liver transplan-
tation between January 1992 and December 2007. We
examined demographic information including gender, age
at transplant and cancer diagnosis, type of immunosuppres-
sion, smoking history, and time to cancer diagnosis. Tumor
characteristics, including clinical and pathologic stage, mode
of presentation, treatment (including adjuvant therapy and
urinary tract reconstruction), and tumor progression were
also evaluated. Postoperative outcomes reviewed include
disease recurrence, allograft function following treatment,
overall and cancer-speciﬁc survival, and length of followup.
No patient had a history of bladder cancer or hematuria
prior to transplantation. Transurethral resection of bladder
tumor (TURBT) with or without intravesical immunother-
apy or chemotherapy (one patient received mitomycin-C)
was used for treating nonmuscle-invasive tumors. Patients
were treated in accordance with the AUA guideline for
the management of nonmuscle invasive bladder cancer2 Advances in Urology
(Hall MC, J Urol, 2007). BCG was used in select patients,
and criteria for consideration of BCG included patients at
high risk for recurrence, large tumors, multifocal tumors,
high-grade disease, or presence of CIS. Surgeon preference
also inﬂuenced the use of intravesical BCG, as multiple
diﬀerent urologists provided treatment to patients in the
current series. BCG was administered as described by
Lamm et al. Radical cystectomy with urinary diversion or
palliative external beam radiotherapy was used for those
with muscle invasive disease. None of the patients with
muscle invasive disease received neoadjuvant or adjuvant
therapies. The radiation ﬁeld was not signiﬁcantly altered in
renal transplant patients, and immunosuppressive regimens
remained unchanged in all patients. Patients were followed
postoperatively at regular intervals per established surveil-
lance protocols.
3.Results
Of the 2,925 renal and 2,761 liver transplant recipients
reviewed, we identiﬁed eight patients following kidney
transplant and three patients following liver transplant (n =
11, 0.2%) who developed bladder cancer. The mean age
at transplantation was 62 ± 13 years (range 38–82 years)
and all were male. Bladder cancer diagnosis was made at a
mean interval of 39 ± 24 months (range 3.5–76 months)
following transplantation. Mean age at the time of diagnosis
was 65 ± 12 years (range 44–83), and mean followup
was 40 ± 27 months (range 12–98 months). Maintenance
immunotherapy protocols included tacrolimus + pred-
nisone, tacrolimus + mycophenolate mofetil + prednisone,
tacrolimus + mycophenolate mofetil, and tacrolimus alone
in 54.5%, 27.3%, 9.1%, and 9.1% of patients, respectively.
It was not necessary to alter immunotherapy protocols
following diagnosis or in the treatment of BUC. There were
no deleterious eﬀects on graft survival or function following
urologic intervention. Prior to urologic intervention, mean
serum creatinine was 1.4mg/dL (range 0.9–2.0mg/dL). At
last followup, serum electrolyte levels were normal, and
mean serum creatinine levelwas 1.5 ± 0.4mg/dL (range 1.0–
2.1mg/dL). Liverfunction tests were not aﬀected by urologic
intervention.
Ten patients presented with gross hematuria, and one
patient was diagnosed incidentally by cross-sectional imag-
ing. Imaging studies performed at the time of diagnosis
revealed no evidence of lymphadenopathy, metastasis, or
upper tract urothelial carcinoma. Two patients with low-
grade T1 BUC were managed by transurethral resection
(TURBT) alone. Three patients with CIS and one patient
with T1 BUC were treated by TURBT and adjuvant intrav-
esical bacille Calmette-Guerin (BCG) immunotherapy. The
patient with T1 disease recurred locally after 7 months
and was treated with a repeat course of BCG. Two of the
patients with CIS recurred at 18 and 12 months: the ﬁrst
was managed with repeat TURBT and a 6-week course of
Mitomycin C; the second received another 6-week course
of BCG. All four patients treated with BCG are alive and
free of further recurrence at a mean followup of 51 ± 22
(36–84) months. One patient with T1 high-grade BUC and
a history of bilateral cutaneous ureterostomies (performed
following transplantation for treatment of vesicoureteral ﬁs-
tula)underwentradicalcystectomy and ureteroureterostomy
andremainsdisease-free withafollowupof98months.None
of the patients with T1 disease progressed to muscle invasive
disease (Table 1).
Muscle invasive transitional cell carcinoma was diag-
nosed in four patients at a median of 3.6 years (range 2
to 6 years) following transplantation (Table 2). Two patients
underwent radical cystectomy with urinary diversion, one
with orthotopic neobladder, and one with percutaneous
allograft nephrostomy tube placement (due to signiﬁcant
scar tissue and adhesions limiting small bowel mobilization
and creation of urinary diversion). Both patients remain
recurrence-free at 24 and 36 months of followup, respec-
tively. Ileal conduit urinary diversion and palliative radiation
were performed in one patient with unresectable disease,
who subsequently died from disseminated intravascular
coagulation 16 months following cancer diagnosis. One
patient received palliative XRT and died of diﬀuse liver
and pulmonary metastases 12 months following treatment.
Criteria for consideration of palliative XRT include evidence
ofmetastases atthetime ofdiagnosisofmuscleinvasive BUC
and unresectable disease.
4.Discussion
The increased risk for the development of malignancies
following renal and liver transplant is well documented [9].
Of special interest to urologists is the increased incidence
of genitourinary malignancies, including kidney and bladder
cancer, following transplantation [10]. Transplant recipients
are up to 3.3-times more likelyto developBUCthan the gen-
eralpopulation[4].Morealarmingly, recentdataalsosuggest
that renal transplant recipients and patients with end-stage
renal disease present with higher-stage [5], biologically more
aggressive tumors [11] and experience worse outcomes than
thegeneralpopulation[11].Theetiologyofincreasedriskfor
BUCamongtransplant recipientsis multifactorial[5],andin
addition to common risk factors for BUC such as smoking,
also includes risk factors unique to the transplant recipient,
such as direct cytotoxic damage from immunosuppressive
agents [12], impaired DNA repair mechanisms in immuno-
compromisedpatients[13],impairedprotectionagainstviral
oncogenes [14], and urinary tract infections [15].
The incidence of de novo BUC following renal and liver
transplantation in our series is 0.27% and 0.11%, respec-
tively, and is comparable to other series. The University
of California, San Francisco, reported the development of
de novo BUC in 0.08% of over 6000 renal transplant
recipients [7] while The University of Wisconsin reported
a 0.19% incidence of BUC after renal transplantation [4].
The United Network for Organ Sharing (UNOS) database
(1986 to 2001) reported a similarly low prevalence (0.024%)
of post-transplantation BUC [7]. Conversely, Kamal et al.
[3] reported a higher rate (0.37%) of BUC following renal
transplantation inEgyptthanobservedinthepresentcohort.Advances in Urology 3
Table 1: Characteristics of patients with nonmuscle-invasiveTCC of the bladder.
P a t i e n t n u m b e r 1 , 2 3456 7
A g e a t t r a n s p l a n t 6 6 7 78 26 66 3 4 5
Type of transplant Liver Renal Renal Renal Liver Renal
Age at diagnosis 66 79 83 72 65 47
Immunosuppression FK, MMF, Pred FK, Pred FK FK, MMF FK, Pred FK, Pred
Clinical stage T1NxMx T1NxMx TisNxMx TisNxMx TisNxMx T1N0Mx
Histology TCC TCC CIS CIS CIS TCC
Grade Low Low High High High High
Treatment TURBT TURBT TURBT TURBT TURBT Cystectomy, ureteroureterostomy
Adjuvant therapy None BCG BCG BCG BCG Mitomycin C
Followup (months) 28, 24 40 36 84 42 98
Recurrence None Local Local None Local None
FK: tacrolimus; MMF: mycophenolate mofetil; Pred: prednisone; CIS: carcinoma in site; TURBT: transurethral resection bladder tumor; BCG: bacille-
CalmetteGuerin.
Table 2: Characteristics of patients with muscle-invasive TCC of the bladder.
Patient number 1 2 3 4
Age at transplant 38 58 60 66
Type of transplant Renal Liver Renal Renal
Age at diagnosis 44 60 63 70
I m m u n o s u p p r e s s i o n F K ,P r e d F K ,M M F ,P r e d F K ,P r e d F K ,P r e d
Pathologic stage T3aN0M0 T3N2M0 T2N0M0 T2N0M1
Histology TCC, CIS TCC TCC TCC
Grade High High High High
Treatment Cystectomy, allograft nephrostomy Cystectomy, neobladder Palliative XRT, Ileal conduit Palliative XRT
Followup (months) 24 36 16 12
Metastasis (months) None None None Liver, pulmonary (12)
Status Alive Alive Deceased (DIC) Deceased
FK: tacrolimus;MMF: mycophenolatemofetil;Pred: prednisone; CIS: carcinoma in site;TURBT: transurethral resectionof bladdertumor; DIC: disseminated
intravascularcoagulation; XRT: external beam radiotherapy.
The authors accounted for this discrepancy by the high
prevalence of bilharzial infestation among the Egyptian
population; and there was evidence of bilharzial cystitis in
ﬁve of the seven cases reported by Kamal et al. [3].
As a result of perioperative and induction immuno-
suppressive therapy used in the immediate posttransplant
period, transplant recipients experience the greatest risk
of developing bladder cancer within the ﬁrst 6 years
after transplantation [11]. Numerous reports document
the rapidly progressive nature of bladder cancer in the
transplant population [7, 8]. Comparison of transplant
recipients from the Israel Penn International Transplant
Tumor Registry to adults in the general population (from
the Surveillance, Epidemiology, and End Results database)
revealed a more advanced cancer stage at diagnosis in trans-
plant recipients as well as a worse stage-stratiﬁed disease-
speciﬁc survival [11]. Immunosuppressive therapy alters the
host-tumor relationship by inhibition of IL-2 stimulated
T-cell proliferation, enhancement of tumor angiogenesis,
and a dose-dependent reduction in DNA repair capability,
resulting in increased biologic aggressiveness, and likely
explains why transplantation confers a poor prognosis for
cancer outcomes [11]. While most primary diagnoses of
BUC in the general population are low-grade superﬁcial
disease [16], a majority of our cohort presented with high
grade disease, and muscle invasion and nodal metastases
were noted in 4 and 2 patients, respectively. Although
recent data have demonstrated favorable outcomes utilizing
neoadjuvant chemotherapy in patients with muscle-invasive
bladder cancer, the patients in the current series were
treated prior to the widespread utilization and acceptance
of neoadjuvant chemotherapy [17]. Neoadjuvant cisplatin
can be considered in solid organ transplant recipients
[18], but no speciﬁc selection criteria exist as data remain
limited; its use should be approached with the same caution
one would use administering adjuvant chemotherapy to
immunosuppressed transplant recipients. However, reason-
able cancer-speciﬁc survival was achieved after aggressive
therapy. The survival rates of 90% (pTxNxMx) and 50%
(≥pT2) at a mean followup of 40 ± 27 months in
our cohort are comparable to the 5-year overall survival
observed in large series following cystectomy in nontrans-
plant patients with pT2 and pT3a BUC (77% and 58%,
resp.) [19]. Our ﬁndings suggest that early and aggressive4 Advances in Urology
screening should be considered in transplant recipients
[5, 11].
To our knowledge, there are no published recommenda-
tions for the management of immunosuppression after sur-
gical resection of BUC. However, some have suggested
that for patients with localized disease, no alteration in
immunosuppression is required [20]. The experience with
adjuvant cisplatin-based chemotherapy in renal transplant
recipients is limited, but it has been used in those with
well functioning and poorly functioning allografts [7, 21].
Doseincrease and the sideeﬀect proﬁle are adversely aﬀected
because most immunosuppressive medications have sys-
temic eﬀects such as nephrotoxicity (cyclosporine) or bone
marrow suppression (cyclophosphamide, mycophenolate)
[7]. However, decrease of immunosuppressive medications
is possible without rejection since the chemotherapeutic
cytotoxic agents are themselves immunosuppressive and
may prevent allograft rejection [7]. Some have argued that
cyclosporineitselfincreases therisk ofmalignancy compared
to other immunosuppressive medications and, therefore,
should not be part of standard regimens [7]. Additional data
are needed to support this concept. The risks of continued
immunosuppression merely to preserve the allograft when
faced with a known, aggressive malignancy are unclear and
deserve investigation [7].
Hematuria was the main presenting symptom in the cur-
rent study. While hematuria in renal transplant recipients
can have several etiologies, it requires thorough evaluation
with urinalysis and culture, upper urinary tract imaging,
and cystoscopy [22]. Urinary cytology is reliable and has a
signiﬁcantly low false-positive rate in renal transplant recip-
ients [23]. Newer diagnostic modalities such as ﬂuorescent
in-situ hybridization and tumor markers have not been
evaluatedinthetransplantpopulation[22].Whilepreviously
reported data have demonstrated an increased incidence
(66.6%)ofuppertractBUCinsmallseriesofrenaltransplant
recipients with bladder tumors [24], no upper tract disease
was identiﬁed in our cohort. Interestingly, none of the
11 patients who developed BUC had a previous smoking
history, a well-recognized risk factor for the development of
BUC.
The optimum management and clinical outcomes of
bladder cancer in renal and liver transplant recipients
are not well deﬁned, and treatment is dependent upon
disease stage [22]. For patients with Ta or T1 low-grade
disease, TURBT may be both diagnostic and therapeutic.
The use of adjuvant intravesical therapies such as BCG
and Mitomycin C should be considered for patients at
high risk for recurrence (large tumors, multifocal tumors,
high-grade disease, or presence of CIS) [22]. While BCG
h a sb e e ns h o w nt ob em o r ee ﬀective than Mitomycin C
to prevent recurrence and disease progression [36], its
use in immunocompromised patients has been cautioned
[4, 37]. BCG is a live attenuated strain of Mycobacterium
bovis that acts as a recall antigen and evokes a nonspeciﬁc
immune response [3], which carries the risk (1 in 12,500
patients) of severe tuberculous reaction, sepsis, and death
among immunosuppressed patients [4, 37]. The eﬃcacy of
intravesical BCG in immunosuppressed patients has also
been questioned. However systemic immunosuppression
maynotalwaysinducealocalimmunosuppressiveeﬀect,and
therefore the bladder immunologic-inﬂammatory reaction
obtained with BCG may maintain its eﬃcacy [27, 37].
While Buzzeo et al. [4] refrained from using BCG in
immunosuppressed patients, Palou et al. [27]r e p o r t e ds a f e
administration of intravesical BCG in 3 renal transplant
recipients. It should be noted that while there were no
adverse reactions to BCG, all 3 patients were treated
with prophylactic isoniazid and rifampin [27]. The safe
administration of intravesical BCG without concomitant
antituberculin prophylaxis has also been reported in 3
immunosuppressed renal transplant recipients [3, 28]. In
the present study, we demonstrate the safe and eﬃcacious
administration of adjuvant intravesical BCG therapy in 4
immunosuppressed transplant recipients. Caution is advised
prior to administration of intravesical therapy, as mortality
due to general visceral deﬁciency has been reported in a
transplant recipient following BCG treatment [38]. Given
the limited data regarding the safety of intravesical BCG
in immunosuppressed patients, we advocate its use only in
select patients while maintaining a high degree of clinical
suspicion for sepsis and administration of prophylactic
antibiotics on a case by case basis. Ciproﬂoxacin was used
in a single dose before each BCG treatment in 80% of our
patients.
For patients with muscle-invasive disease, radical cys-
tectomy oﬀers the best chance at cure and is technically
feasible in kidney and liver transplant recipients [7, 22].
Reported outcomes of radical cystectomy in renal transplant
recipients are summarized in Table 3. It deserves mention
that the rate of muscle invasive BUC observed in our
cohort (36%) was higher than that typically seen in the
generalpopulation.Althoughimmunosuppressed transplant
patients may be at higher risk to develop more aggressive
disease, the current series is too small to draw deﬁnitive
conclusions. Prolonged survival and graft preservation have
been demonstrated after radical cystectomy in transplant
recipients [3, 7]. Reconstructive options range from uri-
nary diversion with incontinent (ileal conduit, cutaneous
ureterostomy, nephrostomy) or continent urinary diversions
(ileal neobladder). Ileal conduit urinary diversion, which
reduces exposure of urine to the absorptive bowel mucosa,
should be used in patients with signiﬁcant renal dysfunction
[22],while orthotopicsubstitutionisfeasiblein patientswith
a creatinine clearance of >40mL/min [3, 7, 25]. Radical
cystectomy should be performed in appropriate situations,
and in some patients with advanced disease, cystectomy may
not be feasible. One patient in the cohort underwent pallia-
tive radiation and ileal conduit urinary diversion following
aborted cystectomy, for the purpose of providing local
symptom control. Radical cystectomy with urinary diversion
did not impact on graft function or survival in the current
cohort.
Given the high incidence (up to 41%) [26]o fs y n c h r o -
nous upper tract TCC in renal transplant recipients, some
advocate that prophylactic bilateral native nephroureterec-
tomies be performed at the time of cystectomy [7, 26]. Lang
et al. [25], conversely, found no evidence of upper tract TCCAdvances in Urology 5
Table 3: Summarized data on all cases of radical cystectomy and urinary diversion performed for postrenal transplant bladder cancer [3].
Study
Number of
radical
cystectomies
Type of urinary diversion (n) Followup
(months) Oncologic outcome (n) Graft function (n)
Present 3
Neobladder (1)
Allograft nephrostomy (1)
Cutaneous ureterostomies (1)
24–98 NED (3) Stable (3)
Kamal et al. [3] 5 Neobladder (5) 3–24 NED (3)
Mets (2) Stable (5)
Lang et al. [25] 4 Neobladder (4) 11–118 NED (3)
Local recurrence (1)
Stable (3)
Chronic allograft
nephropathy (1)
Master et al. [7]3 Neobladder (2)
IC (1) 10–105
NED (1)
Ureteric recurrence (1)
Paravaginalrecurrence (1)
Stable (3)
Kao et al. [26]4 I C ( 4 ) 4 – 3 9 NED (3)
Mets (1) Unknown
Palou et al. [27] 1 IC (1) 10 NED (1) Stable (1)
Wang et al. [28]0
Giessing et al. [29] 1 Neobladder (1) 20 NED (1) Stable (1)
Perabo and
Schultze-Seemann [30] 1 Neobladder (1) 8 NED (1) Stable (1)
Colombo et al. [31] 1 Neobladder (1) 8 NED (1) Stable (1)
Schmidt et al. [32] 1 Unknown Unknown Unknown Unknown
Lam et al. [33] 1 IC (1) Unknown Unknown Unknown
Lemmers and Barry [34] 2 IC (2) 6–24 NED (2) Stable (2)
Tuttle et al. [35] 1 IC (1) 14 NED (1) Stable (2)
NED, no evidence of disease; IC, ileal conduit; Mets, metastases.
in 75% of patients undergoing prophylactic nephroureterec-
tomy. Prophylactic nephroureterectomy was not performed
in the current cohort, and followup studies to date reveal
no evidence of metachronous upper tract disease. The
allograft is rarely the source of BUC and in the vast majority
of cases can be preserved [24]. Given the morbidity of
nephroureterectomy in this complex population, we agree
that prophylactic nephroureterectomy should be reserved
for patients with high-risk features, such as documented
multifocal disease and CIS.
The current study is limited by sample size and retro-
spective design. Reporting bias may havealso occurred in the
early years of the study, prior to eﬀective data acquisition.
Additionally, although all patients were screened for bladder
cancer prior to renal transplant, we cannot exclude the
presence of a pre-existing tumor. Given the short preclinical
latency of BUC [39], however, pre-existing tumors would
likely have been detected at the time of ureteral stent
removal in the early post-operative period. Therefore, given
the short preclinical latency period and the thorough pre-
transplantevaluation,factorsassociatedwithtransplantation
more likely contributed to tumorigenesis as opposed to
increased surveillancein renaland livertransplant recipients.
Additionally, the mean duration from renal transplant to
diagnosis of bladder cancer was 3.3 years, and such a long
period between renal transplantation and BUC development
suggests that these tumors were not present prior to trans-
plantation.
5.Conclusions
We report encouraging oncologic outcomes in eleven pa-
tients undergoing deﬁnitive therapy without compromising
allograft function. The use of intravesical BCG is possible in
select immunosuppressed patients with CIS or nonmuscle-
invasive disease. Aggressive extirpative surgery and urinary
diversion is technically feasible and should be considered in
transplant recipients with muscle invasive BUC and a good
performance status.
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